Heng Xu
China Pharmaceutical University
ORCID: 0000-0002-7748-2621Immunology and MicrobiologyMedicineBiochemistry, Genetics and Molecular Biology
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Top 100%percentile
Indexed papers
0in pilot corpus
Papers
Driven by 5 papers. Top paper: “Faculty Opinions recommendation of Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.”.
Faculty Opinions recommendation of Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature(2020)10.3410/f.736876409.793570258
N/A
0 citations
Heng Xu, Jun Yang
Faculty Opinions recommendation of The human tumor microbiome is composed of tumor type-specific intracellular bacteria.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature(2020)10.3410/f.738032617.793577444
N/A
0 citations
Heng Xu, Jun Yang
18 citations
Heng Xu, Joel Gelernter, Rachel L. Kember, Henry R. Kranzler, Sylvanus Toikumo
2 citations
Heng Xu, Rachel L. Kember, Henry R. Kranzler, Sylvanus Toikumo
41 citations
Yaru Luo, Siyu He, Ying Lu, Yanqiu Gong, Li Gao +21 more